Mobile platform supports users in addiction recovery

Q2i, developers of patient engagement technologies, has announced Heywood Medical Group will be utilizing its Opioid Addiction Recovery Support (OARS) software to support patients with addiction recovery.

As the opioid epidemic continues to grow, patients and providers are searching for access to support tools capable of supporting individuals with opioid addition. OARS offers a healthcare portal through a mobile app for easy access to providers when users need support in their addiction recovery. The platform aims to reduce relapses, inpatient admission and readmissions, overdoses and emergency room visits.

“We are compelled to use every tool at our disposal to fight the addiction crisis in our region. OARS technology will help Heywood Medical Group physicians to more effectively respond to our patient needs, help improve patient outcomes and support the delivery of exceptional care," said Heywood Healthcare President and CEO Win Brown, BA, MSB, MHA. "As an independent and progressive healthcare system focusing on innovative ways to address the opioid crisis, OARS empowers our healthcare team to provide an up-to-date, comprehensive level of care that supports the recovery process for our patients fighting addiction."

As well as offering an avenue to users, OARS gives healthcare teams the ability to monitor and support patient progress in real-time. These data analysis tools give providers an inside look at a patient's recovery, helping identify trends and hazardous behavior to notify family or emergency services.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.